- Home
- DSM vs PGEN Comparison
DSM vs PGEN Comparison
Compare DSM & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- PGEN
- Stock Information
- Founded
- DSM 1989
- PGEN 1998
- Country
- DSM United States
- PGEN United States
- Employees
- DSM N/A
- PGEN N/A
- Industry
- DSM Investment Managers
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- PGEN Health Care
- Exchange
- DSM Nasdaq
- PGEN Nasdaq
- Market Cap
- DSM 303.5M
- PGEN 292.6M
- IPO Year
- DSM N/A
- PGEN N/A
- Fundamental
- Price
- DSM $6.12
- PGEN $0.78
- Analyst Decision
- DSM
- PGEN Buy
- Analyst Count
- DSM 0
- PGEN 5
- Target Price
- DSM N/A
- PGEN $7.00
- AVG Volume (30 Days)
- DSM 161.7K
- PGEN 922.5K
- Earning Date
- DSM 01-01-0001
- PGEN 11-14-2024
- Dividend Yield
- DSM 3.97%
- PGEN N/A
- EPS Growth
- DSM N/A
- PGEN N/A
- EPS
- DSM N/A
- PGEN N/A
- Revenue
- DSM N/A
- PGEN $3,963,000.00
- Revenue This Year
- DSM N/A
- PGEN N/A
- Revenue Next Year
- DSM N/A
- PGEN $426.76
- P/E Ratio
- DSM N/A
- PGEN N/A
- Revenue Growth
- DSM N/A
- PGEN N/A
- 52 Week Low
- DSM $4.69
- PGEN $0.76
- 52 Week High
- DSM $6.05
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- DSM 55.38
- PGEN 39.38
- Support Level
- DSM $6.09
- PGEN $0.76
- Resistance Level
- DSM $6.18
- PGEN $0.97
- Average True Range (ATR)
- DSM 0.05
- PGEN 0.07
- MACD
- DSM 0.02
- PGEN -0.01
- Stochastic Oscillator
- DSM 73.91
- PGEN 7.90
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.